Decoding gynecologic disease to design new approaches for prevention, detection, and treatment.

Most patients with high-grade serous ovarian cancer respond to first-line platinum chemotherapy — then relapse with disease that no longer responds. We're mapping the cell states that survive treatment and tracking how they re-emerge.

The ovarian tumour microenvironment is profoundly immunosuppressive, leaving checkpoint inhibitors and other immunotherapies largely ineffective. We're developing new therapeutics to reprogram the TME and unleash a durable anti-tumour response.

Women with endometriosis face 2–3× the risk of ovarian cancer. We're tracing the cellular transitions from benign lesion to malignant transformation — catching the process before it progresses.